

## CPHI North America expanding Bioproduction focus for 2025

09 May 2024 | News

**Surge in purchasing executive attendance is clear signal of demand for wider supply chain partner options**



CPHI North America reports soaring attendance and palpable excitement on the show floor, as investment returns and biologics show high growth in second half of 2024. The event, the largest CPHI event held in the Americas, saw a 16% increase in critical buyer attendees, with 4,000 participants and 370+ exhibitors. Expectations are that next year's event will continue this pattern with 5000 attendees and over 400 exhibitors.

In particular, the Bioproduction area will expand to over 50 exhibitors emphasizing the expanding role North American companies are playing in supporting robust bioproduction needs.

Sarah Griffin, Event Manager - Pharma Brand US at Informa Markets, commented: "This year, we have observed and continue to anticipate that supporting the biologics supply chain is crucial to meeting expanding regional needs. This support is a vital aspect of the show, especially as pharmaceutical professionals in North America seek increasingly secure and robust supply chain options within Bioproduction."

The 2024 edition of CPHI North America demonstrated a significant uptick in industry engagement, with over 80 speakers presenting on a wide array of topics crucial to the pharma sector's future – from supply chain economics to technologies revolutionizing drug manufacturing and solutions for meeting sustainability goals. A notable highlight was the increased participation from purchasing teams and R&D professionals at the show, reflecting the event's strategic focus on attracting larger buying audiences and fostering new partnerships.

In fact, during a keynote session at the event, BioPlan Associates Managing Partner and a CPHI Annual Report expert, Eric Langer said that the expectation across all the biologics CDMOs he has spoken with is that 'within the next six months they anticipate a return to the pre slow down levels of growth, with a very positive outlook ahead in the next 12-18 months'. BioPlan data released at the event forecast that bio CDMO growth for small, mid, and large companies, is expected to return to the normal 10% -14% growth rate within the next three to six months.

Looking ahead to 2025, CPHI North America will unveil a much larger dedicated Bioproduction area, underscoring the growing significance of biopharmaceutical manufacturing. This addition comes as a response to several key factors, including capacity constraints at major CMOs, a notable surge in FDA approvals of biologic drugs such as mAbs, advanced therapies and ADCs, as well as a raft of strategic investments by pharmaceutical companies to enhance their bioproduction infrastructure. This new feature will include a separate content theatre offering a focused platform for showcasing the latest advancements and facilitating discussions in bioproduction.

Sarah Griffin, Event Manager of US Pharma at Informa Markets, commented, "The feedback we received from exhibitors and attendees has been overwhelmingly positive. The introduction of a qualification process for attendees notably enhanced networking, amplifying the palpable buzz on the show floor. The large turnout indicates the pharma industry's eagerness to learn from one another and foster vital partnerships, and our team is already gearing up for an even bigger and busier event next year."

The 2024 event also featured an innovative approach to engaging early-career professionals and students, which will be expanded next year with a dedicated badge for early professionals. This initiative aims to support the next generation of industry leaders and provide them with valuable networking and development opportunities. Likewise, there will be a large presence of early-stage companies with a bigger Start-up Market next year.

In addition to the in-person event, all recorded content from CPHI North America 2024 is available on CPHI Online, allowing attendees to revisit presentations and discussions. This digital extension not only provides continuous value to the pharma community but also allows them to connect with suppliers and partners around the year.

For more information, please visit [www.informamarkets.com](http://www.informamarkets.com).

For media enquiries, please contact:

Alex Heeley or Nidhi Narain

De Facto Communications

T: +44 (0) 203 735 8165 / +44 (0) 7834784764

E: [n.narain@defacto.co.uk](mailto:n.narain@defacto.co.uk) / [a.heeley@defacto.co.uk](mailto:a.heeley@defacto.co.uk)